Home
About
Overview
Sharing Data
ORCID
Help
History (17)
Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
Emergency preparedness of families of children with developmental disabilities: what public health and safety emergency planners need to know.
The Pediatric Critical Care Transfusion and Anemia Expertise Initiative Consensus Conference Methodology.
Cationic conjugated polymers with tunable hydrophobicity for efficient treatment of multidrug-resistant wound biofilm infections.
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
See All 17 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
Paul B, Rodriguez C, Usmani SZ. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy. Drugs. 2022 Apr; 82(6):613-631.
View in:
PubMed
subject areas
B-Cell Maturation Antigen
Biological Therapy
Humans
Immunotherapy, Adoptive
Multiple Myeloma
Neoplasm Recurrence, Local
Standard of Care
authors with profiles
Saad Usmani MD